Fig. 1From: Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic reviewTrial selection and use of fluid-based biomarker endpoints in clinical trials investigating Alzheimer disease-modifying treatments per development phase. Overview of the methods (A). Percentage of trials using a fluid-based biomarker (B). Percentage of trials using a fluid-based biomarkers as primary, primary and nonprimary, or nonprimary endpoint (C). Percentage of trials using CSF, blood or both (D)Back to article page